Symbiotec Pharmalab is a Madhya Pradesh-based contract development and manufacturing organisation (CDMO) specialising in corticosteroid and steroidal-hormone APIs. The company is launching its maiden IPO worth ₹1,757 crore from August 24 to August 27, 2026. The issue includes a ₹150 crore fresh issue and an offer for sale (OFS) of ₹1,607 crore. The shares are expected to list on BSE and NSE on September 1, 2026.
Looking beyond IPOs? Explore Finology 30.
Table of Contents
- Symbiotec Pharmalab IPO Details
- Symbiotec Pharmalab IPO GMP
- Symbiotec Pharmalab Business Overview
- Symbiotec Pharmalab Financial Performance
- Symbiotec Pharmalab IPO Objectives
- Symbiotec Pharmalab IPO Valuation
- Symbiotec Pharmalab IPO Peer Comparison
- Symbiotec Pharmalab IPO Subscription and Quota Allocation
- Key Strengths of Symbiotec Pharmalab IPO
- Key Risks of Symbiotec Pharmalab IPO
- Should You Apply for Symbiotec Pharmalab IPO?
- Symbiotec Pharmalab IPO Important Dates
- Conclusion
The Symbiotec Pharmalab IPO has a price band of ₹938 to ₹988 per equity share. At the upper price band, the minimum retail investment for one lot of 15 shares is ₹14,820.
The IPO is largely an offer for sale, with only ₹150 crore being raised through fresh equity. This distinction is important because the proceeds from the OFS will go to the selling shareholders, while the fresh issue proceeds will be available to the company.
| IPO Parameter |
Details |
| Issue Size |
₹1,757 crore |
| Fresh Issue / OFS |
₹150 crore / ₹1,607 crore |
| Price Band |
₹938–₹988 |
| Lot Size |
15 shares |
| Minimum Investment |
₹14,820 at upper band |
| Face Value |
₹2 per share |
| Post-Issue Market Cap |
~₹6,348.5 crore |
| Listing |
BSE and NSE |
The IPO opens on August 24, 2026 and closes on August 27, 2026. Allotment is expected to be finalised on August 28, followed by refund initiation and share credit on August 31. The expected listing date is September 1, 2026.
Eligible employees will receive a discount of ₹90 per share.
/content-assets/b445d11653654609b4cbadac23d0b879.png)
Get all the latest updates on the Symbiotec Pharmalab IPO, including its price band, issue structure, lot size, and key offer details.
As of August 20, 2026, the Symbiotec Pharmalab IPO is trading at a Grey Market Premium (GMP) of approximately ₹190 to ₹225 per share.
Based on the upper price band of ₹988, this represents an indicative premium of around 19% to 23%.
| GMP Indicator |
Estimate |
| IPO Upper Price |
₹988 |
| Current GMP |
₹190–₹225 |
| Indicative Listing Price |
₹1,178–₹1,213 |
| Potential Gain per Lot |
₹2,850–₹3,375 |
For a retail investor applying for one lot of 15 shares at ₹988, the indicative gain based on the current GMP range would be approximately ₹2,850 to ₹3,375.
However, GMP is an unofficial and volatile indicator. It does not guarantee the actual listing price or listing gains. The final listing performance can be influenced by subscription levels, broader market conditions and investor sentiment.
Symbiotec Pharmalab operates in the API and CDMO space, with a specialised focus on corticosteroid and steroidal-hormone APIs. As of FY2025, the company had a 36.2% global volume market share in corticosteroid APIs and 44.2% in steroidal-hormone APIs.
The company manufactures its products at facilities located in Indore, Madhya Pradesh.
Business Model
Symbiotec generates 100% of its revenue from API sales, primarily covering corticosteroid and steroidal-hormone APIs. Alongside API manufacturing, it provides contract development and manufacturing services to specialty pharmaceutical and nutraceutical companies.
Its customer base includes more than 200 customers across over 40 countries. International markets contributed 67.04% of revenue in FY2026, highlighting the company's substantial export exposure.
The company's business can be broadly understood through three key characteristics:
-
Specialised API portfolio: Focus on corticosteroid and steroidal-hormone APIs.
-
Global customer base: More than 200 customers spread across 40+ countries.
-
International revenue exposure: 67.04% of FY2026 revenue came from international markets.
Customer Concentration
Despite its broad customer base, revenue remains concentrated among its largest customers.
FY2024 Customer Concentration
| Customer Group |
FY2024 |
| Top 10 Customers |
61.65% |
| Top 5 Customers |
48.51% |
FY2025 Customer Concentration
| Customer Group |
FY2025 |
| Top 10 Customers |
55.90% |
| Top 5 Customers |
42.27% |
FY2026 Customer Concentration
| Customer Group |
FY2026 |
| Top 10 Customers |
57.59% |
| Top 5 Customers |
43.01% |
The top 10 customers accounted for 57.59% of revenue in FY2026, while the top five contributed 43.01%. This creates a meaningful concentration risk because a reduction in orders or loss of a major customer could affect revenue and profitability.
Symbiotec Pharmalab recorded growth in revenue and EBITDA between FY2024 and FY2026, although PAT growth was comparatively modest.
FY2024 Financial Performance
| Financial Metric |
FY2024 |
| Revenue from Operations |
₹716.25 Cr |
| EBITDA |
₹177.04 Cr |
| EBITDA Margin |
24.72% |
| PAT |
₹100.06 Cr |
| PAT Margin |
13.84% |
| Total Borrowings |
— |
FY2025 Financial Performance
| Financial Metric |
FY2025 |
| Revenue from Operations |
₹751.55 Cr |
| EBITDA |
₹206.11 Cr |
| EBITDA Margin |
27.42% |
| PAT |
₹96.79 Cr |
| PAT Margin |
12.80% |
| Total Borrowings |
₹540.92 Cr |
FY2026 Financial Performance
| Financial Metric |
FY2026 |
| Revenue from Operations |
₹869.15 Cr |
| EBITDA |
₹231.97 Cr |
| EBITDA Margin |
26.69% |
| PAT |
₹109.90 Cr |
| PAT Margin |
12.60% |
| Total Borrowings |
₹387.91 Cr |
Revenue increased from ₹716.25 crore in FY2024 to ₹869.15 crore in FY2026, translating into a 10.16% CAGR. EBITDA grew at a faster 14.47% CAGR, rising from ₹177.04 crore to ₹231.97 crore over the same period.
PAT increased from ₹100.06 crore in FY2024 to ₹109.90 crore in FY2026, representing a 4.86% CAGR. However, the PAT margin declined from 13.84% to 12.60% during the period.
Debt Reduction
The company reduced total borrowings from ₹540.92 crore in FY2025 to ₹387.91 crore in FY2026.
The fresh issue also has a debt reduction component. Out of the ₹150 crore fresh issue, ₹112.5 crore will be used to repay outstanding borrowings. As of March 2026, the company had ₹349.7 crore of remaining debt.
This means the fresh capital will partly strengthen the company's balance sheet rather than being directed entirely towards expansion.
Symbiotec Pharmalab Q1 FY27 Performance
For the quarter ended June 2026, Symbiotec Pharmalab reported:
-
Revenue: ₹203.1 crore
-
Profit: ₹29.9 crore
The Q1 FY27 numbers provide an early indication of the company's performance in the new financial year and will be relevant for investors evaluating the sustainability of its growth.
The ₹1,757 crore IPO consists of a ₹150 crore fresh issue and a ₹1,607 crore OFS.
Fresh Issue
The company plans to use the ₹150 crore fresh issue proceeds as follows:
The fresh issue therefore provides limited new capital for business expansion, with the majority earmarked for debt repayment.
Offer for Sale
The ₹1,607 crore OFS is being offered by existing shareholders.
| Selling Shareholder |
OFS Value |
| Satwani Holdings LLP |
₹144 Cr |
| Rosewood Investments |
₹988 Cr |
| India Business Excellence Fund-III |
₹475 Cr |
The OFS proceeds will go to the selling shareholders and will not accrue to Symbiotec Pharmalab. As a result, around 91.5% of the total issue size is an OFS.
At the upper price band of ₹988, the IPO implies a valuation of approximately 51.72 times FY2026 earnings, based on an FY2026 EPS of ₹19.10.
The company's NAV is ₹184.69 per share, resulting in a P/BV ratio of approximately 5.35 times. Its Return on Net Worth (RoNW) stands at 9.48%.
| Valuation Metric |
Symbiotec Pharmalab |
| FY2026 EPS |
₹19.10 |
| P/E |
~51.72x |
| NAV per Share |
₹184.69 |
| P/BV |
~5.35x |
| RoNW |
9.48% |
The valuation presents a mixed picture. Symbiotec's P/E is lower than the selected peer companies, but its RoNW is also comparatively lower. This means investors need to assess the valuation alongside the company's specialised API positioning, growth profile and profitability.
Want to compare Symbiotec Pharmalab's valuation with other recent mainboard issues across sectors? Use the IPO dashboard to track pricing, issue size and listing trends.
As of March 31, 2026, Symbiotec's valuation can be compared with selected listed pharmaceutical and API companies.
| Company |
P/E |
RoNW |
| Symbiotec Pharmalab |
51.72x |
9.48% |
| Concord Biotech |
61.07x |
14.00% |
| Divi's Laboratories |
87.80x |
16.50% |
| Cohance Lifesciences |
95.02x |
7.00% |
| Laurus Labs |
109.36x |
16.80% |
Symbiotec has the lowest P/E among the companies listed above. However, its 9.48% RoNW is below Concord Biotech, Divi's Laboratories and Laurus Labs, although it is above Cohance Lifesciences.
Therefore, the lower P/E should not be viewed in isolation. The company's profitability metrics and specialised API exposure also need to be considered when assessing the IPO valuation.
The IPO has been divided among different investor categories.
| Investor Category |
Reservation |
| QIBs |
50% |
| NIIs/HNIs |
15% |
| Retail Investors |
35% |
| Employees |
Reserved portion |
The anchor investor book-building process is scheduled for August 21, 2026.
Retail investors can apply for a maximum of 13 lots, equivalent to 195 shares. At the upper price band of ₹988, the maximum application amount is ₹1,92,660.
Symbiotec Pharmalab has several factors that could support its investment case.
1. Global Position in a Specialised API Segment
The company reported a 36.2% global volume market share in corticosteroid APIs and 44.2% in steroidal-hormone APIs as of FY2025. Its specialised product focus gives it a distinct position within the API market.
2. Consistent Revenue Growth
Revenue increased from ₹716.25 crore in FY2024 to ₹869.15 crore in FY2026, representing a 10.16% CAGR. EBITDA grew at a faster 14.47% CAGR over the same period.
3. Strong International Exposure
With 67.04% of FY2026 revenue generated from international markets, the company has a substantial global customer base spanning more than 40 countries.
4. Debt Reduction
Borrowings declined from ₹540.92 crore in FY2025 to ₹387.91 crore in FY2026. The IPO's fresh issue will further allocate ₹112.5 crore towards debt repayment.
5. Positive GMP
The current GMP of ₹190 to ₹225, as of August 20, indicates an unofficial premium of around 19% to 23% over the upper IPO price band. However, this remains an indicative market signal rather than a guaranteed return.
The investment case also carries several risks that investors should consider before applying.
1. Customer Concentration Risk
The top 10 customers contributed 57.59% of FY2026 revenue, while the top five contributed 43.01%. A significant reduction in orders from a major customer could therefore have a material impact on the company's financial performance.
2. Product Concentration Risk
Symbiotec derives 100% of its revenue from APIs, specifically corticosteroid and steroidal-hormone APIs. Any regulatory, pricing or demand-related disruption affecting these products could have a significant impact on the business.
3. Regulatory and Compliance Risk
The company exports to more than 40 countries and operates in a highly regulated pharmaceutical environment. Regulatory inspections and compliance requirements, including those associated with authorities such as the US FDA and EMA, create operational risks. Adverse observations or import restrictions could affect exports and operations.
4. High Valuation Multiple
At the upper price band, the IPO is valued at approximately 51.72x FY2026 earnings. While this is below the P/E multiples of the selected peers, Symbiotec's RoNW of 9.48% remains moderate. Investors therefore need to assess whether the company's growth and specialised market position justify the valuation.
5. Large OFS Component
The OFS accounts for approximately 91.5% of the total issue size. Since OFS proceeds go to existing shareholders rather than the company, only ₹150 crore of the ₹1,757 crore issue directly raises fresh capital for Symbiotec.
6. Competition
The API and CDMO industry includes established companies such as Divi's Laboratories, Laurus Labs and Concord Biotech. Competitive intensity can result in pricing pressure and margin challenges.
The Symbiotec Pharmalab IPO presents a combination of specialised market positioning, international exposure, steady revenue growth and declining borrowings. At the same time, investors need to account for customer concentration, product concentration, regulatory exposure, moderate RoNW and the very high OFS component.
For Retail Investors
For investors focused on short-term listing gains, the current GMP indicates a potentially positive listing, with an indicative premium of 19% to 23%. However, GMP is unofficial and can change before listing.
For long-term investors, the IPO appears more suitable for a cautious approach. The company's specialised API position and financial growth are positives, but customer concentration, regulatory risks and valuation need to be monitored.
Investors considering a long-term position may also watch subsequent financial results, including Q2 FY27 performance, along with developments in customer diversification.
For HNIs and Institutional Investors
The IPO provides exposure to a specialised API and CDMO business with a significant international presence. However, the large OFS component and RoNW of 9.48% warrant careful evaluation and position sizing.
Application Strategy
Based on the supplied analysis:
-
Retail investors: Applying for 1 to 3 lots can limit the amount of capital exposed to the IPO.
-
HNIs: Subscription levels and anchor investor participation can be considered alongside valuation before applying.
-
Risk-averse investors: The IPO may not be suitable given the customer concentration, regulatory exposure and valuation risks.
-
High-growth investors: Investors seeking businesses with higher growth and margins should compare Symbiotec's profile with alternative opportunities before applying.
| IPO Event |
Date |
| Anchor Investor Allotment |
August 21, 2026 |
| IPO Opens |
August 24, 2026 |
| IPO Closes |
August 27, 2026 |
| Allotment Finalisation |
August 28, 2026 |
| Refund Initiation |
August 31, 2026 |
| Share Credit to Demat |
August 31, 2026 |
| Listing on BSE/NSE |
September 1, 2026 |
The Symbiotec Pharmalab IPO 2026 offers exposure to a specialised corticosteroid and steroidal-hormone API business with a significant global market position. Revenue grew at a 10.16% CAGR between FY2024 and FY2026, while EBITDA grew at 14.47%. The company also reduced borrowings from ₹540.92 crore to ₹387.91 crore during FY2025-FY2026.
However, the investment case is not without concerns. More than 57% of revenue comes from the top 10 customers, the company is entirely dependent on its API portfolio, and approximately 91.5% of the IPO is an OFS. At ₹988, the IPO also commands a P/E of around 51.72x despite a RoNW of 9.48%.
Overall, the IPO may appeal to investors seeking exposure to a specialised API and CDMO business, but the valuation, customer concentration and OFS structure make a cautious assessment important. The GMP indicates positive listing sentiment as of August 20, 2026, but it should not be treated as a guarantee of listing gains.
Disclaimer: This analysis is based on the information provided and publicly available information as of August 20, 2026. GMP is unofficial and subject to change. Investors should read the DRHP and other offer documents carefully and assess their risk appetite before making an investment decision.